Skip to main content

Table 2 Information of CAR-T cells in production

From: High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma

NO. Preparation days T cells (×108) Fraction of CAR+ T cells (%) CAR+ T cells
×106/kg
1 10 2.4 18.0 1.0
2 12 35.7 15.0 10.0
3 13 6.7 9.0 1.0
4 12 5.6 14.7 1.6
5 10 3.2 18.0 1.0
6 10 15.7 10.0 2.7
7 13 7.3 30.0 4.0
8 13 24.7 10.0 4.1
9 12 1.0 30.0 0.5
10 12 10.7 15.0 2.1
11 14 6.8 15.0 2.1
12 14 9.5 15.0 2.0
13 13 4.2 18.0 1.0
14 11 3.6 50.0 3.0
15 9 12.0 20.0 4.0
16 10 16.5 10.0 2.9
Median 12 7.1 15.0 2.1